^
Association details:
| Biomarker: | NTRK2 fusion |
|---|---|
| Cancer: | Fibrosarcoma |
| Drug: | Vitrakvi (larotrectinib) (TrkB receptor inhibitor, TrkC kinase inhibitor, TrkA receptor inhibitor) |
| Direction: | Sensitive |
Evidence:
Title:
New sarcoma drug approved for use in England
Excerpt:
We’re delighted to announce that a new drug, larotrectinib, has been approved for the treatment of certain sarcomas in England. ‘Sarcoma UK welcomes today’s approval of larotrectinib. Made available for use by the Cancer Drugs Fund and approved by NICE (National Institute for Health and Care Excellence) larotrectinib is a new type of ‘histologically-independent’ drug that targets tumours based on their genetic makeup. It works by targeting the specific NTKR genetic abnormality in tumours meaning patients are treated according to the genetics of their tumour rather than where it is in the body.
Source:
Title:
Larotrectinib in Treating Patients With Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute Leukemia
Excerpt:
...Patients must have a histologic diagnosis of infantile fibrosarcoma with an NTRK1, NTRK2, or NTRK3 fusion identified in a Clinical Laboratory Improvement Act/College of American Pathologists (CLIA/CAP) certified laboratory....
Trial ID:
Source:
Title:
Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network
Published date:
09/02/2020
Excerpt:
The ORR with larotrectinib in adult and pediatric patients with sarcoma harboring an NTRK fusion was 74% (95% CI 52–90) and 94% (95% CI 82–99), respectively. Objective responses were observed in patients with soft tissue sarcomas, GISTs, and infantile fibrosarcoma.
DOI:
10.1016/j.annonc.2020.08.2232
Source:
Title:
Larotrectinib efficacy and safety in pediatric TRK fusion cancer patients.
Published date:
05/26/2019
Excerpt:
18 (47%) had infantile fibrosarcoma, 15 (39%) other soft tissue sarcoma, 2 (5%) thyroid cancer and 1 (3%) each had gastrointestinal stromal tumor, melanoma, or mesoblastic nephroma.…In 34 evaluable pts, the overall response rate was 94%: 12 CRs, 18 confirmed PRs, and 2 PRs pending confirmation; 2 had stable disease....Larotrectinib treatment resulted in a high and durable response rate in pediatric pts with TRK fusion cancer...
DOI:
10.1200/JCO.2019.37.15_suppl.10010
